SEC Tracker
Get the app

ARS Pharmaceuticals SPRY

ARS Pharmaceuticals (SPRY) reports stock option grant.

Donn Casale, insider filing for SPRY

Form
4
Filed
Importance
Routine
  1. Oct 1, 2026 - Stock option granted
  2. 1,036,923 shares underlying the option
  3. Vesting begins 25% on July 7, 2027
  4. Expiration date September 30, 2036

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when ARS Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.